France
Highly experienced BD-Corporate Development Executive with proven track record establishing successful partnerships and closing transactions including: Mergers, Acquisitions, in and out licensing JV’s and profit sharing deals. Experience managing BD&L projects across the life cycle from discovery to late stage and marketed products. Identification of opportunities, diligence, deal structuring, negotiation and closing. True global work experience: 15 years living in Australia and Asia Pacific including work assignments in Japan, China, Korea, Australia, South East Asia plus 15 plus years in Europe/US including US, EU5, Central Europe plus MENA and Latam. Experience with MNC's - Aventis (Hoechst-Roussel), Quintiles Transnational and Takeda as well as Biotech - Serono, Epirus. Strong focus and expertise on early stage builds and starts ups, Market Entry strategy which includes General Management experience (P&L responsibility) at both country and regional level with specific expertise in emerging markets, having established legal entities, built,developed and run from scratch several country affiliates.
Life science consultancy focused on Biotechnology
Based in the Global HQ leading Global BD&L , reporting to Chief Strategy Officer
Epirus Biopharmaceuticals is a Global Biosimilars company, NASDAQ listed (EPRS) with operations and offices in U.S. (Boston), Switzerland (Zug), Netherlands (Utrecht). Initially conceived as a VC funded biotech which spun out from Percivia LLC ( now part of Johnson and Johnson Group). The company develops a range of monoclonal antibody biosimilar products for indications primarily focussed on inflammation , autoimmune disease, oncology and rare diseases. The company's first product (infliximab) was approved and launched in 2014. Key responsibilities include: Design, development and implementation of Global Business Development and Corporate Development Strategy. Establishing joint ventures and partnerships in key markets in public and private sectors across Latam, Asia Pacific, MENA, CIS. Developing localised manufacturing strategies for emerging markets. Leading all BD transactions through discovery, diligence, financial modelling deal structuring and negotiations. Seeking and securing additional sources of non dilutive funding through VC, PE and sovereign wealth funds. Successful IPO listing on NASDAQ